One To Watch

Curie.Bio

A venture firm and therapeutics accelerator focused on launching and supporting early-stage biotechnology companies developing new medicines. Curie.Bio combines seed investment with hands-on drug discovery and development support to help founders build therapeutics startups and advance programs toward clinical proof of concept.

Company Overview

Curie.Bio operates as a hybrid venture capital and operating platform for biotechnology startups. The firm provides seed funding alongside integrated scientific and operational support to founders developing new therapeutic companies.

The model is designed to help early-stage biotech founders progress from an initial scientific idea to the type of data package needed to raise a Series A financing and advance drug discovery programs.

Headquarters and Global Presence

Curie.Bio is headquartered in Boston, Massachusetts.

The firm works with biotechnology founders internationally and supports portfolio companies across North America and Europe.

Founding and History

Curie.Bio was founded in 2022 by biotechnology entrepreneurs Alexis Borisy, Christoph Lengauer and Zach Weinberg.

The firm launched with several hundred million dollars in capital and positioned itself as a new model for biotech venture funding, combining seed investment with embedded drug discovery expertise.

Therapy Areas and Focus

Curie.Bio does not develop proprietary drugs directly. Instead, it helps create and fund portfolio companies developing therapeutics across multiple disease areas, including:

Oncology
Immunology and inflammation
Neurology and psychiatric disorders
Other rare and serious diseases addressed by portfolio companies

Programs across the portfolio span a variety of drug modalities depending on the underlying scientific opportunity.

Technology Platforms and Modalities

Curie.Bio is modality-agnostic and supports portfolio companies working across different therapeutic approaches, including:

Small-molecule drug discovery
Monoclonal antibodies and biologics
RNA-based therapeutics
Cell and gene therapy approaches

Its operating model pairs founders with experienced drug discovery scientists and operators who assist with experimental design, development strategy and early operational infrastructure.

Key Personnel

Zach Weinberg, Co-Founder and Chief Executive Officer
Alexis Borisy, Co-Founder and Chairman
Christoph Lengauer, Co-Founder

Strategic Positioning

Curie.Bio positions itself as both a seed investor and an operational partner. The firm provides capital together with a team of experienced drug developers who work closely with founders to define development plans, recruit teams and reach early milestones.

The organization also manages multiple investment vehicles, including seed and follow-on funds designed to support portfolio companies through early development stages.

FAQ Section

Curie.Bio is a venture firm and therapeutics accelerator that helps founders create biotechnology companies developing new medicines.

The firm combines seed investment with direct operational involvement, providing drug discovery expertise, development planning and scientific support alongside funding.

Curie.Bio focuses primarily on seed-stage biotechnology companies, often helping founders build companies around early scientific concepts.

Portfolio companies typically develop therapies in oncology, immunology, neuroscience and other disease areas with significant unmet medical need.

No. Curie.Bio primarily invests in and helps launch independent biotechnology companies that develop therapeutics.

The firm supports multiple drug modalities, including small molecules, biologics, RNA therapeutics and cell-based therapies.

Key milestones include successful launch of new portfolio companies, advancement of early drug programs toward clinical testing and follow-on financing rounds for portfolio startups.

Want to Update your Company's Profile?